Perioperative morbidity is a public health priority, and Introduction: surgical volume is increasing rapidly. With advances in technology, there is an opportunity to research the utility of a telemedicine-based control center for anesthesia clinicians that assess risk, diagnoses negative patient trajectories, and implements evidence-based practices.
Introduction
Perioperative complications collectively contribute to numerous deaths around the world 1 . Following inpatient surgeries, the estimated 30-day mortality is between 1% and 5% [2] [3] [4] [5] [6] [7] [8] [9] [10] , and between 5% and 10% of surgical patients will die in the following year 4, 5, 8, 11 . Furthermore, 10% to 20% of surgical patients experience major complications such as heart attacks, chronic pain 12 , infections and blood clots following their procedures 6, 9, 10, 13 . Although some complications are unavoidable, based on the nature of the particular surgical procedure or non-modifiable patient characteristics 9, 14, 15 , others may be preventable through early identification of patient risk factors and the use of tailored treatments.
Several factors, besides technical aspects of surgeries, contribute towards preventable perioperative complications. Clinicians [16] [17] [18] [19] , including anesthesia care teams (typically comprising anesthesiologists and certified registered nurse anesthetists [CRNAs] ), sometimes fail to implement and adhere to evidence-based standards of care. Many clinicians believe that they are in compliance with guidelines, when in reality they are not 20 . In the United States, differing backgrounds and perspectives of anesthesiologists and CRNAs can undermine effective collaboration among team members, potentially compromising patient care 21, 22 . Clinicians also experience cognitive overload in the operating room (OR), and limitations in cognitive capacities impair information processing 23 and decision making abilities [24] [25] [26] . In addition, the rapidly evolving OR environment and complex patient responses to surgery and anesthesia make it challenging for clinicians to accurately assess patients' shifting risks.
Telemedicine and integrated machine learning (ML) are two promising approaches for addressing cognitive and information overload, dynamically focusing resources where needed, and reducing accidental variations in care quality. However, there is no prospective evidence on telemedicine or ML in the OR context. There is an urgent need for rigorous research investigating the utility of a telemedicine-based control center to dynamically assess risk, diagnose negative patient trajectories, implement evidence-based practices, and improve outcomes for surgical patients. A collaborative telemedicine solution for the OR, through the early and accurate identification of potential risks, could facilitate the development of tailored plans for patient care risk mitigation and management [27] [28] [29] . It could also enhance meaningful teamwork between CRNAs and anesthesiologists, act as a complementary support for anesthesia care teams in the OR, help to decrease cognitive overload and bias, and facilitate evidence-based care.
To address this deficit, our interdisciplinary team, including academic and clinical leaders, has developed a prototype anesthesiology control tower (ACT) 30, 31 . Our previous pilot work has demonstrated the usefulness and usability of the ACT 30, 32 . We have also developed ML algorithms for real time decisionsupport instruments [33] [34] [35] [36] , developed the institutional infrastructure to maximize OR integration of the ACT, and evaluated the feasibility of conducting a large scale randomized control trial using the ACT 31 . In this protocol we outline the Telemedicine Control Tower for the OR: Navigating Information, Care and Safety (TECTONICS) trial, which is a large-scale randomized controlled trial (RCT) to empirically evaluate the effectiveness of the ACT on preventing clinically relevant adverse perioperative outcomes and improving perioperative care.
We hypothesize that the integrated ACT system in the TECTON-ICS trial will improve evidence-based quality of perioperative care metrics and prevent clinically relevant adverse perioperative outcomes (postoperative delirium, renal failure, respiratory failure, and 30-day mortality).
Participants and setting
The study is a single center, randomized, controlled, phase 3, pragmatic superiority trial at Barnes Jewish Hospital (BJH) in St. Louis, MO. All adults (18 years and older) undergoing surgical procedures in these operating rooms will be included. Children are excluded in this study. Labor and operative delivery is conducted in a separate administrative area and is also excluded unless it occurs in the main surgical ORs. There are no other exclusion criteria related to procedure type, comorbid illnesses, or planned disposition other than the requirement that some anesthesia clinician be requested (excluding e.g. organ procurement and minor procedures performed without anesthesiology services) and the requirement for the procedure to take place in an operating room (excluding sedation-based procedure suites such as the cardiac diagnostic laboratory).
An estimated 10,000 patients will be enrolled annually, and enrollment will be over four years for approximately 40,000 total patients enrolled ( Figure 1 ). Cases started during the hours of operation of the ACT will be included regardless of the stop time.
This study has been approved by the Human Research Protection Office at Washington University (St. Louis, MO # 201903026) for enrollment with a waiver of consent. Participant data is collected from the electronic health record (EHR) of BarnesJewish and its affiliated hospital and clinic databases until 30-days after their surgery. 
Interventions
The participant groups are intraoperative telemedicine support from the ACT ("intervention") and usual care.
Description of the ACT
The ACT has been established in a location remote from the OR with sophisticated hardware and software. It is staffed by at least two clinicians from the research team (an anesthesiologist and one or more other clinicians). Intraoperative data streams used by the ACT clinicians include real-time access to the hospital's EHR, web-based visualization of vital signs and waveforms, treatment guidelines, protocols for care, as well as AlertWatch® (Ann Arbor, MI) (Figure 2, Figure 3 ). AlertWatch® is a Food and Drug Administration-approved patient monitoring and alerting system that displays integrated patient information. AlertWatch® was primarily conceptualized for use in individual ORs; we have modified the AlertWatch® software based on stakeholder engagement and feedback for use in the ACT, creating a customized dashboard and interface specifically designed for the telemedicine setting 32 . The ACT AlertWatch® version that we developed in our preliminary studies is a customized research product with innovative information technology and communication components and is distinct from the current commercial product in several important respects. Real-time forecasting (from the machine-learning algorithms discussed below) of adverse outcomes for individual patients is provided to ACT clinicians. BJH is currently installing high definition cameras in the ORs; video feeds will be incorporated in the ACT if these are available during the trial. Video or audio will not be stored.
Intervention group
In ORs randomized to intervention, ACT clinicians contact OR clinicians in two phases. First, the ACT messages the OR clinician an individualized risk assessment and considerations/ recommendations based on the preoperative evaluation and real time information from the monitors in the OR. The recommendations are geared towards (1) preventing major complications (Table 1 ) based on patients' specific risk profiles (e.g. history of stroke, hypertension, type 1 diabetes, coronary artery disease, valvular heart disease, pulmonary disease) and (2) adhering to general quality of care indicators ( Table 2 ). The recommendations are based on the best currently available evidence (e.g. intensive insulin management in type 1 diabetes). OR clinicians are encouraged to reply to the message with specific concerns they would like to discuss, risk assessments they believe to be erroneous, and additional monitoring that they would like the ACT to perform. The second phase occurs during procedures. The ACT monitors physiologic and process alerts generated by AlertWatch® and ML algorithms, filters these alerts for those believed relevant and actionable, and contacts the anesthesia team where deemed appropriate. OR clinicians receiving notification from the ACT may choose to carry out whatever course of action they deem clinically appropriate. Anesthesia clinicians in the OR have access to the institution's "clinical" AlertWatch software, but do not have access to the "research" view.
Usual care
In ORs randomized to usual care, the ACT monitors patients, but the ACT clinicians does not contact the OR clinicians unless the ACT clinicians believe it to be clinically necessary for patient safety purposes (e.g. neuromuscular blockade without evidence of hypnotic agent administered). Concomitant care is provided in the usual perioperative setting with no modifications based on the trial. Anesthesia clinicians in the OR have access to the institution's "clinical" AlertWatch software, but do not have access to the "research" view.
Risk forecasting algorithms
Using data from over 110,000 patients, we developed calibrated ML algorithms to predict adverse postoperative outcomes. The details of the dataset and algorithm development are published elsewhere [34] [35] [36] . Briefly, we implemented deep neural network models for 30-day mortality, acute kidney injury, and postoperative ventilatory failure among other anesthesiology-relevant The team in the ACT receives data form the electronic health record, web-interfaced monitors in the operating room (OR), video cameras in the OR, multipath convolutional neural network machine learning algorithms, and alerting software has been customized to provide maximum utility in an ACT. The team weaves together disparate data strands, and collaboratively formulates a plan to address the patient's risk and optimize outcomes. The plan is discussed collegially with OR clinicians, who exercise judgement in delivering the best individualized perioperative management to each surgical patient. Dynamic data from OR patient monitors. (The photo was taken in our prototype ACT). CRNA, certified registered nurse anesthetist. . It is administered every 12-24 hours depending on clinical context while in the ICU. All delirium assessments within 7 days will be included.
Postoperative respiratory failure
Defined as mechanical ventilation for greater than 24 hours after surgery, or unplanned postoperative reintubation and mechanical ventilation within 48 hours of surgery 39 . Planned staged operations are excluded.
Postoperative acute kidney injury
Diagnosed when any of the following three criteria are met: (i) an increase in serum creatinine by 50% compared with preoperative within 7 days, (ii) any increase in serum creatinine > 0.3 mg/dL in 48 hours, or (iii) oliguria (urine output <0.5 mL/kg/hr for 6-12 hours) 33, 40, 41 . Table 2 . Secondary outcome measures and definitions.
Measurement Definition
Temperature management Temperature ≥ 36°C at end of surgery Antibiotic redosing Antibiotic redosing compliant with guidelines developed by the institutional pharmacy and therapeutics committee. Fresh gas flow rates Proportion of patients with efficient fresh gas flow for ≥90% of the anesthetic maintenance period outcomes based on routinely collected clinical data. We tested numerous other prediction methods, and found that deep neural networks processing extensive patient information (i.e., demographic characteristics, surgical risk, co-morbidities) as well as time series physiological data (e.g., blood pressure, temperature, heart rate) predict outcomes such as death with high area under receiver operator characteristics curve (0.880), acceptable sensitivity (~50%) and excellent specificity (~95%). We adapted models to improve their interpretability and incorporated advanced post-processing methods to uncover the data which drives individual predictions. The training of these deep neural network models jointly estimates data filtering and imputation steps with prediction
33
. We implemented appropriate data validation and quality filtering steps for the live environment and display forecasts of mortality updated every 5 minutes. In contrast to standard forecasting models, we have previously demonstrated that ML and data mining approaches for patients in ICUs are markedly superior in predicting clinical outcomes such as mortality 42 . The feasibility of this integration is supported by a previous successful trial, where members of our investigative team, using live data from the EHR, implemented ML algorithms to guide a rapid response team in medical wards [43] [44] [45] [46] .
Over the course of the TECTONICS study, with ongoing acquisition of high-resolution data and outcomes on thousands of surgical patients, our algorithms will undergo regular evaluation and refinement. Periodically updating the model will be necessary, which we plan to do at 6-month intervals with newly collected data in the control arm. We will also use a human expert to review the face validity of the model's predictions and most important input features. Such a dynamic feedback loop will continuously improve and adjust the model. We will test for the overall percentage of correct forecasts, the percent of correctly forecasted events, and accuracy when data include noise and missing values on several adverse perioperative outcomes. One key metric that we will evaluate and compare will be the sensitivity at 95% specificity, since it is important to maintain a high specificity (i.e., low false alarm rate) for meaningful decision support. Validation techniques will include cross-validation 47 and systematically different hold-out samples (e.g. distinct time periods or OR locations).
Outcome measures and data acquisition
The primary objective is to determine whether the ACT system is effective in preventing clinically relevant adverse perioperative outcomes including thirty-day postoperative mortality, postoperative delirium, postoperative respiratory failure and postoperative acute kidney injury. Secondary objectives are to determine whether the ACT system is effective at improving perioperative quality of care metrics. The study outcomes will be assessed according to established criteria (Table 1 and  Table 2 ).
Multiple sources are used for standardized data collection. Data on patient outcomes and perioperative care metrics is extracted from the EHR. Preoperative patient characteristics, comorbidities, surgical and clinical history, as well as perioperative and immediate post-operative information are pulled from the EPIC EHR (Verona, WI, USA). Additional postoperative patient outcomes data (for sub-studies) will be obtained from clinical registries (American College of Surgeons National Surgical Quality Improvement Program 48 , Society of Thoracic Surgeons 49 ,) as well as the EHR. BJH determines vital status through multiple mechanisms including follow-up contact and state death databases. Non-mortality outcomes are not tracked after discharge from hospital. Although the development of incident serious acute kidney injury (AKI) or delirium post-discharge is possible, we anticipate that these will be uncommon enough to not warrant large-scale surveillance.
Data on clinician responses to individual alerts, generated from the AlertWatch® Control Tower platform, is logged by ACT staff to a database for qualitative studies and internal quality improvement.
Assignment of treatments
The 58 ORs (all the ORs at BJH excluding "remote" locations, procedure suites, and labor and delivery) are 1:1 randomized daily to receive intraoperative support from the ACT or usual care without any form of stratification. In other words, participants are randomized in clusters whose size randomly depends on the number of cases assigned to a room. The randomization script for the TECTONICS trial has been incorporated into the AlertWatch® ACT infrastructure, and runs automatically early every morning.
Due to the nature of the intervention it is not possible to blind OR clinicians since feedback alerts from the ACT inform them that they are in the intervention group. However, patients and those evaluating outcomes are blinded to group assignment.
Sample size calculation and recruitment
In recent years, more than 20,000 surgeries have been performed annually in the Barnes Jewish Hospital main ORs. However, the ACT is only staffed during work-week hours and when the assigned attending anesthesiologist is available. During our pilot, we made efforts to ensure staffing during all appropriate times; however, under half of cases took place during ACT staffed times. We therefore conservatively estimate that 10,000 patients will participate per year, but we anticipate that more rapid accrual is likely based on more complete recent staffing. The TECTONICS trial will be adequately powered to answer with precision whether the ACT system has a meaningful impact on clinically relevant outcomes (primary outcomes, see Table 3 ) and quality of care metrics (secondary outcomes, see Table 4 ). Despite the fact that we are evaluating multiple surrogate outcomes, the very large sample size will provide adequate statistical power to determine whether or not there is improvement with the ACT system. Individuals with multiple surgeries within 30 days will be analyzed with the assignment of their index surgery. Individuals with multiple independent encounters (>30 days separation) will be treated as distinct observations. Surgeries which take place outside BJH will not be accounted for.
Assessing Hawthorne and contamination effects
We anticipate a possible contamination (or learning) effect over time in the usual care group. Clinicians are included in both intervention and control ORs (possibly on the same day) and may become sensitized to the standards of practice and the surrogate outcome measures being tracked, leading to "overlapping" improvements in these measures (as well as clinical outcomes) in both groups over the course of the study. This learning effect might manifest most strongly among 1.5% 84% (>80%)* *The adjusted power was calculated assuming a cluster-randomized design allowing for an intracluster correlation between 0.005 and 0.01 and varying number of patients per OR. The current incidence estimates on which these power analyses are based are consistent with findings in our previous studies 4,5,12,55,56,57,58,50,51 as well as from the ACTFAST 2 pilot study, where we have approximations of these complications from ~110,000 (mostly inpatient) surgical patients at our institution over 5 years. clinicians who spend time in the ACT. Furthermore, with the knowledge that clinical behaviors are being observed, there is a high likelihood of a Hawthorne effect 59,60 . In the reverse of the usual Hawthorne problem, the effect of being observed in the intervention arm represents part of the actual effect of the intervention; knowing that they are being observed, clinicians may feel more accountable to following perioperative best practices, and this is a meaningful effect. However, the noncontact rooms are also aware of the trial and enjoy the same improvement, falsely decreasing the estimated effect size. The data we have obtained prior to instituting the ACT will be useful in assessing the extent of contamination. Specifically, we will assess the intensity/frequency of contamination by comparing the outcomes of the control group patients to those of matched patients who had similar surgeries, demographics, and health conditions during the immediate period prior to the ACT implementation. We will also analyze control arm results in 3-month time bins (with baseline data for reference) to evaluate secular tends which may represent contamination, as well as the magnitude of clustering design effects.
Analysis of primary and secondary outcomes
Comparisons between groups during the randomized study will be with parametric and non-parametric statistical tests, according to the distributions of the measures of interest. Fisher's exact or χ 2 test will be used to assess differences between proportions (the majority of assessments). Contingency statistical tests will be used to compare occurrence of hypotension, hyperglycemia, hypoglycemia, and hypothermia between groups; and unpaired t-test or Mann-Whitney U-test, as appropriate, will be used to compare the durations of these occurrences between groups. All comparisons will use the intention-to-treat principle.
Results in statistical tests with a p value <0.005 will be viewed as providing compelling evidence, whereas results with a p value between 0.05 and 0.005 will be interpreted as providing suggestive evidence 61 . We will report p-values adjusted for multiple hypothesis tests (within the primary and secondary outcome blocks) using permutation methods that account for the correlation across outcomes 62 . Within the secondary outcomes, false-discovery-rate control will be reported 63 .
Handling of missing data
We anticipate that the prospectively collected data will be high quality with few missing outcomes. AKI is informatively missing in patients who are judged as low risk by the surgical team and do not have assessments of postoperative creatinine or urine output. Delirium is similarly infrequently assessed at our institution in patients who do not require intensive care unit admission. A screening bias in both outcomes is possible where patients in the treatment arm are more accurately identified as elevated risk and checked for complications. Ventilatory failure is unlikely to occur in the 48-hour time window among discharged patents. We will report the number of patients without assessments for each outcome. The primary analysis will treat patients discharged without measures of AKI or delirium as negative. Patients who are informatively censored by death will be treated as positive for other outcomes. All outcomes will be required to be incident. Individuals without preoperative measures of renal status or delirium will be assumed to have normal values.
Adverse event and safety monitoring
This study will have a Safety Monitoring Committee (SMC) according to the National Institute of Nursing (NINR) Research Data Safety Monitoring policy. The SMC will be comprised of a small group of experts with at least two members independent of the study team. They will be responsible for reviewing all adverse events, compliance with the IRB requirements, investigator compliance, minimizing risks and protecting the confidentiality of participant data. The SMC will review study data every six months.
The study team will prepare reports for the SMC, NINR and the IRB. In the event a serious adverse event occurs that is deemed to be reasonably associated with the conduct of the study by an external SMC, the study may be halted. Local regulatory agents in agreement with the study principle investigator may decide to stop the study at any time.
Strengths, limitations and alternative strategies
The TECTONICS trial has important strengths. It is a pragmatic RCT conducted in a high volume, real-world clinical setting that incorporates telemedicine for the OR. The adverse outcomes under study are serious and meaningful to patients. The TECTONICS trial can be conducted efficiently as many components of the proposed study are incorporated into existing infrastructures and processes at Washington University: 1) with no known risk associated with the support offered by the ACT, participants are included with a waiver of informed consent; 2) the members of the care team (anesthesiologists, CRNAs, residents and student registered nurse anesthetists) participate in the trial in the course of their routine clinical work; and 3) most of the surrogate and clinical outcomes data are obtained from existing IT resources or from established and ongoing registries 64 . Randomization of ORs is implemented easily, and the process for providing feedback alerts from the ACT does not require any lead-in time or advanced preparation. The study includes all adult surgical-patients at BJH, including both men and women, and those who are recognized to be vulnerable and understudied in clinical research. The feasibility of the trial is enhanced by participation of a highly committed cadre of CRNAs and attending anesthesiologists, student registered nurse anesthetists and residents in the Anesthesiology Department, as well as an experienced team of CRNA and anesthesiology investigators that has established a track record of scientific collaboration and completion of major trials 4,5,55-57, [65] [66] [67] .
There are also relevant limitations. The TECTONICS study will be vulnerable both to Hawthorne and contamination effects. Although we do not think that these effects can be eliminated, we have considered how best to account for them in the analyses. In addition, it will not be possible to ensure blinding 68 of clinicians. However, surgical patients and those evaluating outcomes will be blinded to group assignment. Another major constraint relates to both accuracy and completeness of outcome measures. Outcomes routinely tracked in the EHR are often well represented. However, we know from previous experience that EHR, registry, and patient reported outcomes data are occasionally inaccurate 58 . Missing and inaccurate outcomes data will be partially mitigated by the large number of patients included in the trial, and are expected to be randomly distributed across groups.
Ethics/protection of human subjects
This study has been approved by the Human Research Protection Office at Washington University (St. Louis, MO # 201903026). It satisfies the criteria for a waiver of informed consent (there is minimal risk with the intervention, the research could not practically be conducted without a waiver, and the rights and welfare of patients are not adversely affected by their involvement in the study, and there is no deception requiring additional disclosure) and is being conducted accordingly. This protocol was written in compliance with the SPIRIT Checklist Guidelines for Interventional Trials. Only the minimum necessary private patient information will be collected for the purposes of the study. Any protected health data is kept in a secure digital environment that is digitally encrypted, password protected and limited to research team only. De-identified data may be kept and used in future studies not pre-specified in the above protocol. The investigators are responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data collected.
Data management
The ACT will use clinical applications available to all clinicians to monitor ongoing surgical procedures. These applications can only be accessed over the secure hospital network or by virtual private network logins. This arrangement meets and/ or exceeds Health Insurance Portability and Accountability Act standards for Patient Health Information (PHI) security. AlertWatch® is an approved clinical application at BarnesJewish Hospital, and therefore maintains these same levels of protection. Access to the data collected in this study will be restricted to approved personnel. It is a strict policy that PHI content cannot be reviewed outside of this protected environment. Prior to data analysis, information will be de-identified. When possible, extracts from this project will avoid the use of PHI. De-identified patients can be identified using a special, non-PHI primary key, which we have used previously.
The research material obtained in this proposed trial will consist of the already established infrastructure and resources of the SATISFY-SOS (NCT02032030), NSQIP and STS registry studies, Anesthesiology Control Tower-Feedback Alerts to Supplement Treatments (ACTFAST) 1, 2 and 3 studies, the intra-operative electronic medical record and the AlertWatch® evidence-based alerting system. Patient demographic information and preoperative characteristics are collected and entered into the electronic health record as part of routine clinical care at the Center for Preoperative Assessment and Planning. Perioperative and intraoperative drug administration and vital signs are also charted in the electronic health record.
Data will be maintained for at least 5 years after the end of the grant funding period. Further study record retention will be at the discretion of the study investigator. Data may be used for future studies not mentioned in the protocol.
Publication/data sharing policy
The investigative team is comprised of a range of stakeholders, including scientists, clinical investigators, and relevant end users. We will each disseminate in our respective networks through presentations to relevant stakeholder groups, through peer-reviewed publications, and by providing brief summaries for hospital administrators and policy makers. We will also utilize the BJC Collaborative, which aligns multiple health networks in the region (including rural settings), as a vehicle for dissemination.
Data from the TECTONICS trial will be made available for analysis in compliance with the recommendations of the International Committee of Medical Journal Editors 69 . For this study, individual participant data that underlie the results of the trial will be made available after appropriate de-identification, along with the study protocol and statistical analysis plan. We plan to make this information accessible to researchers who provide a methodologically appropriate proposal for the purpose of achieving the aims of that proposal. Data will be available beginning 9 months and ending 36 months following trial publication at a third-party website. Data requestors will need to sign a data access agreement to gain access to trial data. Proposals should be directed to avidanm@wustl.edu. TECTONICS is registered on clinicaltrials.gov, NCT03923699.
Authorship eligibility and contributorship
Authorship for this study will be given to key personnel involved in study design, data collection, and data analysis. There are no publication restrictions and no professional writers will be involved in the generation of the manuscript. 
Protocol amendments
Protocol amendments will be approved by the steering, operations, safety, and data management committees, communicated to the IRB and NINR, and posted to Clinicaltrials.gov. This protocol corresponds to version 1.1 and was agreed on October 1 2019.
Conclusion
While ML and telemedicine have been extensively studied over the past decade, telemedicine has often been implemented without a strong research foundation. When it has been studied, this has often been done in the context of observational before and after cohort trials. ML algorithms have often been studied for risk calculations and predictions, but there has been limited investigation of their application to improving patient outcomes. In contrast, TECTONICS is designed as a pragmatic, randomized clinical trial including telemedicine and ML. The over-arching strength of TECTONICS is that it combines and leverages a telemedicine initiative with advanced machine-learning algorithms. The net innovation is a fully integrated clinical decision support system, comprised of remote surveillance of patient risks in real-time, human expert judgment, and computer-generated rules. This realization of the ACT concept provides an empowering and unobtrusive socio-technical telemedicine infrastructure and decision support solution for OR teams. The ACT also provides a practical and innovative solution to the challenge of implementing evidence-based guidelines in the OR. Although the ACT system requires an initial modest financial investment, if it proves to be effective in promoting and enhancing evidence-based perioperative care, it is possible that it could lead to decreased costs via improvements in surgical patient outcomes.
The proposed study can have a major impact on healthcare if it demonstrates that the ACT system enhances OR care quality and patient safety while simultaneously increasing teamwork. Following the TECTONICS study, the ACT system will be further refined, and its implementation will be expanded. The logical next step will be to conduct a larger multisite trial focusing on expanded clinical and patient-reported outcomes. We are well positioned to track such outcomes, based on electronic access to ICD codes 58 , our experience in building a patient reported outcomes registry 50, 58, 70 , as well as our collaborations with NSQIP and the Society for Thoracic Surgeons. Importantly, one of the TECTONICS contributors (Kheterpal) is the principal investigator of the Multi-Center Perioperative Outcomes Group (MPOG), which includes data from >4 million patients, and has an established and sophisticated international IT infrastructure. We envisage that future dissemination and implementation of the ACT system could occur efficiently using the MPOG infrastructure.
Throughout the study, we will collect data from ACT users on reach (percent of clinicians and staff eligible who use and engage with the ACT), adoption (user confidence that they will continue to use the ACT after the study ends), implementation (user confidence that the ACT can be consistently delivered as intended), and maintenance (user confidence that the ACT will produce lasting benefits beyond the study) 71 . When planning for wider-scale implementation, we will use established guidelines set-out by the Expert Recommendations in Implementing Change (ERIC) team 72 .
Data availability Underlying data
No data are associated with this article. This protocol originates from a cross-disciplinary group of researchers including perioperative clinicians and data scientists. The project is based at a single academic hospital in North America. The protocol describes a pragmatic clinical trial of a complex systems intervention using machine learning guided remote decision support in anaesthesia care. The primary outcome is a composite of 30-day mortality, postoperative delirium, respiratory failure and acute kidney injury after surgery. The proposed trial is pragmatic in design.
Reporting guidelines
Population: The population includes all adult surgical patients taking place in the main theatre facilities of the trial site. Obstetric patients and other patients undergoing surgery in locations remote to the main theatre facilities are excluded by the sampling method. The study population is restricted to a single academic hospital in a high-income setting.
Intervention: The intervention is complex in design and implementation, but all the components of the intervention have already been piloted and introduced into the system and the technology supporting the trial are not new to the trial site. It is stated that the intervention will change over the duration of the trial as guidelines and updated and machine learning algorithms improve. Will the effect of an evolving intervention be evaluated? The complexity of the intervention should be considered when interpreting the findings of this trial.
Outcome: The outcome is clinically important to patients and healthcare providers. The components of the composite outcome are measured as part of routine care (data extracted from electronic medical records). The mortality component of the composite outcome is robust, but the event rate of the other components will likely be underestimated by this method of data collection.
3.
4.
5.
event rate of the other components will likely be underestimated by this method of data collection. This will not affect validity of the estimate of effect of the intervention. The reviewers wonder what reasoning determined the components of the composite outcome. Why, for example, are cardiovascular events and surgical site infections not included?
Design: The unit of randomisation is the operating room, and randomisation is updated daily. Theoretically, randomisation to a complex intervention within a single institution risks contamination across the arms of the study. The investigators address this concern appropriately in the protocol. The concern of bias introduced by the Hawthorne effect is also addressed in the analysis plan. With a projected sample size of 40000 surgical cases, the proposed trial is sufficiently powered to answer the patient relevant question.
Burden: Despite the complexity of the trial, it does not pose additional burden to healthcare providers. Data collection is part of routine care, provision of the intervention does not rely on the usual healthcare providers, and the institutional review board approved a waiver of consent. The reviewers wonder which ethical considerations were discussed for observing healthcare providers. Is there an agreement for participation process for clinicians who are being observed in this study?
What will be considered an adverse event in this trial? Can examples be given? Will the project use specific criteria to identify adverse events?
Monitoring and evaluation of the program would add value. What is the explicit logical framework connecting the intervention to the outcomes being measured? When reading the result of this trial the reviewers would conceivably be interested in knowing how the intervention lead to a change in management? What factors determined translation of recommendation from the ACT to practice change in theatre? Does the person sitting in the ACT cause variability in the way the intervention is delivered and received? Will the trial measure compliance or adherence to the ACT recommended intervention?
The capital investment and running cost of this intervention must be significant. Future work, investigating the cost of benefit will facilitate considerations around generalisability of this intervention.
This protocol represents an exciting frontier in the field of anaesthesia research. The proposed trial incorporates precision care into routine care, assessed in a pragmatic manner. The reviewers look forward to the results and report of this trial, and future projects that build on this one.
Is the rationale for, and objectives of, the study clearly described? Yes 
